Results 21 to 30 of about 2,131 (185)

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

The Journal of Headache and Pain, 2022
Background Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanezumab therapy.
Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen   +5 more
doaj   +1 more source

Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine

, 2023
Acupuncture and fremanezumab are second-line treatments for migraine prophylaxis. We aimed to compare acupuncture with fremanezumab in the preventive treatment of episodic migraine by using a matching-adjusted indirect comparison analysis (MAIC).
Jing-Tao Liang (14393499), Hui Zheng (58412), Shi-Qi Fan (14526280), Yun-Zhou Shi (12215900), Xin-Yu Xiao (14526283)   +4 more
core   +2 more sources

Fremanezumab [PDF]

pharma-kritik, 2020
Fremanezumab ist der dritte in der Schweiz erhältliche Hemmer des «Calcitonin Gene-Related Peptide» (CGRP). Diese Medikamente sind zur Prävention von Migräneanfällen zugelassen, bisher aber nicht mit anderen präventiven Massnahmen verglichen worden. Am besten werden sie deshalb vorläufig nur im Rahmen von Studien eingesetzt.
openaire   +1 more source

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

The Journal of Headache and Pain, 2021
Background Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy.
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl   +9 more
doaj   +1 more source

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody [PDF]

Анналы клинической и экспериментальной неврологии, 2023
Introduction. High prevalence of migraine and its impact on quality of life requires the development of original agents. In 2020, fremanezumab, a new calcitonin gene-related peptide monoclonal antibody was authorized in Russia.
Larisa A. Dobrynina, Maksim A. Afanasev, Anastasia V. Belopasova, Maria V. Gubanova, Ekaterina V. Baydina   +4 more
doaj   +1 more source

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials

Frontiers in Neurology, 2020
Background: Fremanezumab (TEV-48125) is a fully-humanized immunoglobulin G isotype 2a selective monoclonal antibody that potently binds to calcitonin gene-related peptide (CGRP).
Bixi Gao, Nan Sun, Yanbo Yang, Yue Sun, Mingjia Chen, Zhouqing Chen, Zhong Wang   +6 more
doaj   +1 more source

PEARL study protocol:A real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

, 2021
Lay abstract Fremanezumab is an injectable biologic medication that targets calcitonin gene-related peptide, a substance released in the nerves and blood vessels during a migraine attack that plays a role in migraine pain.
Lyras, Leonidas, Konings, Martijn, Ashina, Messoud, Cohen, Joshua M., Kokturk, Pinar, Amin, Faisal Mohammad, Tassorelli, Cristina, Mitsikostas, DImos Dimitrios, Kokturk P., Cohen J. M., Mitsikostas D. -D., Tassorelli C., Ashina M., Konings M., Lyras L., Amin F. M., Cristina Tassorelli, Leonidas Lyras, Martijn Konings, Dimos-Dimitrios Mitsikostas, Faisal Mohammad Amin, Pinar Kokturk, Messoud Ashina, Joshua M Cohen   +23 more
core   +3 more sources

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study

BMC Neurology, 2023
Background There have been very few real-world studies reported in the literature solely focusing on fremanezumab in Asia. This study aimed to evaluate the efficacy and safety of fremanezumab in a real-world setting in Japan. Method This single-centered,
Seiya Ohtani, Narumi Watanabe, Keiko Ihara, Nobuyuki Takahashi, Naoki Miyazaki, Kei Ishizuchi, Ryo Takemura, Satoko Hori, Jin Nakahara, Tsubasa Takizawa   +9 more
doaj   +1 more source

Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study. [PDF]

Epilepsia Open
Abstract Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world multicenter retrospective cohort of adults with comorbid migraine and epilepsy treated with anti‐CGRP ...
Romozzi M, Burgalassi A, Ceriello F, Martino P, Sette G, Pistoia F, Placidi F, Centonze D, Pani L, Canonichesi J, Vollono C, Calabresi P, Albanese M, Iannone LF.   +13 more
europepmc   +2 more sources

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

The Journal of Headache and Pain, 2022
Background Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically meaningful way.
Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka, Steve Barash   +5 more
doaj   +1 more source